ergocalciferol

Reactions 401 - 16 May 1992

SErgocalciferol

Polycythaemia and nephrocalcinosis: case reportIn a report from Japan, nephrocalcinosis and polycythaemia

developed in a 23-year-old man with hypophosphataemicvitamin D-resistant rickets which had been diagnosed 21 yearspreviously. He had initially received ergocalciferol </= 320000 U/day for 7 years; the dosage was subsequently reducedafter he developed hypercalcaemia. At aged 18 years, thepatient developed hypertension and hydrochlorothiazide wasadded to his treatment regimen; however, this wasdiscontinued after the onset of hypercalcaemia,hyperphosohataemia and renal insufficiency. At this stage, thepatient’s haemoglobin level was elevated and remained sodespite having been normal prior to hydrochlorothiazidetherapy. The polycythaemia was associated with a reduction inthe total plasma volume Despite recovery of renal function,nephrocalcinosis and polycythaemia persisted.

Comment: This case report highlights the importance ofpreventing these irreversible complications which could leadto further adverse reactionsOkazaki R, et al. Erthyrocytosis in hypophosphatemic rickets: irreversiblecomplication due to nephrocalcinosis after vitamin D and phosphate therapy.Japanese Journal of Medicine 30: 545-547, Nov-Dec 1991 - Japan 800130069

1

Reactions 16 May 1992 No. 4010114-9954/10/0401-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved